1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?

Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?

  • April 2015
  • ID: 3090954
  • Format: PDF
  • By Firstword Pharma

Summary






New data presented at the annual meeting of the American Association for Cancer Research (AACR) this past week has further emphasised the paradigm shift in cancer therapy that PD-1 inhibitors offer.

Focusing on the two most advanced products in this class – Bristol-Myers Squibb's Opdivo and Merck & Co.'s Keytruda – FirstWord is polling US and EU5-based oncologists this week to gauge opinion towards two specific areas of future usage.

In the melanoma market, where both products are already approved as second-line therapies, Bristol-Myers Squibb demonstrated further evidence that Opdivo, when used in combination with its CTLA-4 inhibitor Yervoy, was significantly more effective than Yervoy alone for first-line therapy. Indeed, the Checkmate-069 study demonstrated that in first-line stage III and stage IV melanoma patients, the combination triggered an objective response rate of 61 percent versus 11 percent for Yervoy monotherapy (ViewPoints: Bristol-Myers Squibb ups the stakes with combination melanoma play).

Retaining a first-line presence for the Yervoy franchise in melanoma will be key in allowing Bristol-Myers Squibb to build a franchise position in this indication and meet consensus revenue forecasts. Nevertheless, increased efficacy comes with a notably increased toxicity profile, with 54 percent of combination-treated patients suffering from grade 3 or 4 adverse reactions versus 17 percent of those patients treated with just Yervoy








Quite how this combination will fit into the treatment paradigm remains to be seen, and we are asking oncologists to estimate (based on the Phase II data)…




What percentage of first-line patients they would anticipate being treated initially with the combination of Opdivo and Yervoy?
What percentage of first-line patients they would expect to be initially treated with a more flexible regimen, such as Opdivo with subsequent addition of Yervoy if necessary?
What impact they expect the side-effect profile for the combination of Opdivo and Yervoy to have in limiting use of this combination in the first-line setting?

Switching focus to the second-line treatment of non-small-cell lung cancer, Bristol-Myers Squibb and Merck both continue to demonstrate impressive manoeuvrability in moving Opdivo and Keytruda, respectively, faster to market than expected. With Bristol-Myers Squibb's Checkmate-057 stopped early, Opdivo has now demonstrated survival benefit in both squamous and non-squamous patients, while Keytruda has been filed as a second-line therapy on the strength of data from the Keynote-001 study, Merck confirmed last week (ViewPoints: Merck & Co. ups its game again, but Bristol-Myers Squibb takes lead in NSCLC PD-1 race).

Notably, the FDA has confirmed that it will not require overall survival data for Keytruda prior to approval, which appears to not only remove any overhang that Opdivo could quickly raise barriers to entry in the lung cancer indication, but confirm that Merck – to some extent – will continue to 'piggy-back' on Bristol-Myers Squibb's first-to-market status. A key question is whether this extend to labelling and usage of Keytruda, given that the Keynote-001 study stratified patients by PD-L1 biomarker status (while Opdivo – in the second-line setting at least – has been studied in 'all comers').

On this issue, we are asking oncologists…

To provide their assessment of available data to ascertain whether either Opdivo or Keytruda is more strongly positioned in the second-line NSCLC market?
Whether initial usage of Keytruda will occur in all second-line NSCLC patients or just PD-L1 over expressers, and how labelling and or study design may dictate this?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Synovial Sarcoma - Pipeline Review, H2 2019

Synovial Sarcoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Synovial Sarcoma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2019, provides an overview of the Synovial Sarcoma ...

Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

"Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Non-Small Cell Lung Cancer. ...

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

"Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on